Aligos Therapeutics Inc. (NASDAQ: ALGS), a San Francisco-based biotechnology company, has announced a clinical trial collaboration with Xiamen Amoytop Biotech Co., Ltd, a Chinese pharmaceutical firm. The partnership aims to explore the combination therapy of Aligos’ ALG-000184 with Amoytop’s Pegbing (mipeginterferon alfa-2b) for the treatment of chronic hepatitis B (CHB) virus. The Phase Ib study, which will be conducted in China and overseen by Amoytop, is pending IND approval from Chinese regulatory authorities.
ALG-000184, developed by Aligos, is a potent oral small-molecule capsid assembly modulator (CAM-E) that is currently in a Phase Ib trial. The drug has shown promising results, demonstrating best-in-class reductions in HBV DNA, RNA, HBsAg, HBeAg, and HBcrAg without any viral breakthrough to date. Amoytop’s Pegbing, the world’s first 40kD pegylated interferon α-2b injection, functions by inhibiting viral replication and enhancing immune responses. It is primarily used as a first-line antiviral treatment for CHB in clinical settings. The collaboration between the two companies seeks to leverage the synergistic potential of the combined therapy to improve the clinical cure rate for hepatitis B virus.- Flcube.com
